Memphasys Toekomstige groei

Future criteriumcontroles 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Memphasys.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Life Sciences winstgroei	21.1%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Geen updates

Recent updates

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Memphasys onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

ASX:MEM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (AUD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	1	-4	-4	-3	N/A
3/31/2024	1	-4	-4	-3	N/A
12/31/2023	1	-5	-4	-2	N/A
9/30/2023	1	-4	-4	-2	N/A
6/30/2023	1	-3	-3	-1	N/A
3/31/2023	1	-3	-3	-1	N/A
12/31/2022	1	-2	-3	-1	N/A
9/30/2022	1	-2	-3	-1	N/A
6/30/2022	1	-2	-3	0	N/A
3/31/2022	1	-2	-3	0	N/A
12/31/2021	1	-2	-3	0	N/A
9/30/2021	0	-2	-3	0	N/A
6/30/2021	0	-1	-3	0	N/A
3/31/2021	0	-1	-3	0	N/A
12/31/2020	N/A	-1	-3	0	N/A
9/30/2020	N/A	-1	-3	0	N/A
6/30/2020	N/A	-1	-3	0	N/A
3/31/2020	N/A	-1	-3	0	N/A
12/31/2019	N/A	-1	-3	0	N/A
9/30/2019	N/A	-1	-3	-1	N/A
6/30/2019	N/A	-1	-3	-1	N/A
3/31/2019	N/A	-1	-3	-1	N/A
12/31/2018	N/A	-1	-2	-1	N/A
9/30/2018	N/A	-1	-2	-1	N/A
6/30/2018	N/A	0	-2	-1	N/A
3/31/2018	N/A	-1	N/A	-1	N/A
12/31/2017	N/A	-1	N/A	-1	N/A
9/30/2017	N/A	-1	N/A	-1	N/A
6/30/2017	N/A	-2	N/A	-1	N/A
3/31/2017	0	-2	N/A	-1	N/A
12/31/2016	0	-2	N/A	-1	N/A
9/30/2016	0	-2	N/A	-1	N/A
6/30/2016	0	-2	N/A	-1	N/A
12/31/2015	0	-2	N/A	-1	N/A
9/30/2015	0	-2	N/A	-2	N/A
6/30/2015	0	-2	N/A	-2	N/A
12/31/2014	0	-1	N/A	-3	N/A
9/30/2014	0	-1	N/A	-3	N/A
6/30/2014	0	-1	N/A	-2	N/A
12/31/2013	1	-3	N/A	0	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if MEM's forecast earnings growth is above the savings rate (2.4%).

Winst versus markt: Insufficient data to determine if MEM's earnings are forecast to grow faster than the Australian market

Hoge groeiwinsten: Insufficient data to determine if MEM's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if MEM's revenue is forecast to grow faster than the Australian market.

Hoge groei-inkomsten: Insufficient data to determine if MEM's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if MEM's Return on Equity is forecast to be high in 3 years time

Memphasys Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Memphasys Limited, Annual General Meeting, Oct 25, 2024

New major risk - Shareholder dilution

Full year 2024 earnings released

Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.5 million.

Memphasys Limited announced that it has received AUD 0.5 million in funding

Is Memphasys (ASX:MEM) Using Too Much Debt?

Memphasys (ASX:MEM) Is Making Moderate Use Of Debt

New major risk - Financial position

Memphasys Limited, Annual General Meeting, Feb 14, 2024

New minor risk - Shareholder dilution

Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 4.232268 million.

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.003 loss in FY 2022)

Memphasys Limited, Annual General Meeting, Nov 22, 2023

New minor risk - Financial data availability

Memphasys (ASX:MEM) Is Making Moderate Use Of Debt

New major risk - Market cap size

Memphasys Limited Announces the First Publications of Study Findings by Key Opinion Leaders (KOLs) of the Felix System

Less than half of directors are independent

Memphasys Limited to Report Fiscal Year 2022 Results on Sep 01, 2022

Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 1.6 million.

Less than half of directors are independent

Memphasys Limited Enrolls the Clinical Study on its Felix Device and Treated the First Couple 2

Does Memphasys (ASX:MEM) Have A Healthy Balance Sheet?

Less than half of directors are independent

Memphasys Limited Announces Management Changes

Is Memphasys (ASX:MEM) A Risky Investment?

Memphasys Limited Announces First Felix System Commercial Sale for Clinical Ivf Use

Memphasys Ordinary Shares to Be Deleted from Other OTC

Memphasys (ASX:MEM) Is Making Moderate Use Of Debt

Memphasys Limited Advises That All Remaining Verification Tasks Associated with the Upgraded Felix Device Have Successfully Passed the Verification Process

Memphasys Limited Updates on Assisted Reproductive Biotechnology Products

Memphasys Limited Provides Further Update on the Status of the Remediation Process for the Felix Device

Will Memphasys (ASX:MEM) Spend Its Cash Wisely?

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven